Last reviewed: November 2017
Last updated: November  2016

Summary

Differentials

Common

  • Primary lung cancer
  • Metastatic cancer
  • Hamartoma
  • Infectious

Uncommon

  • Carcinoid tumour
  • Lymphoma
  • Sarcoidosis
  • Rheumatoid arthritis
  • Granulomatosis with polyangiitis (Wegener's granulomatosis)
  • Arteriovenous malformation
  • Intrapulmonary lymph node
  • Pulmonary amyloidosis
  • Mucoid impaction

Contributors

Authors VIEW ALL

Erik E. Folch

Associate Director

Chief, Complex Chest Disease Center

Co-director, Interventional Pulmonology Massachusetts General Hospital

Harvard Medical School

Boston

MA

Disclosures

EEF is the global principal investigator for the NAVIGATE trial, sponsored by Medtronic. He has also served as scientific consultant for Boston Scientific in the development of advanced bronchoscopic techniques.

Peter J. Mazzone

Director of Lung Cancer Program

Director of Lung Cancer Screening Program

Director of Education

Respiratory Institute

Cleveland Clinic

Cleveland

OH

Disclosures

PJM has been paid to participate in clinical advisory board meetings for Oncimmune, InDi, Nucleix, Grail, and Oncocytelooking, all companies interested in developing molecular biomarkers for the evaluation of lung nodules/ lung cancer; he does not have a contractual agreement to disseminate product information for any of these companies. PJM has participated in research supported by InDi Veracyte, that was paid to his institution. He has also participated in research with in-kind support from Oncimmune and 20/20 Genesystems.

Peer reviewers VIEW ALL

Consultant Physician

Royal Brompton Hospital

Chelsea & Westminster Hospital

London

UK

Disclosures

PLS declares that he has no competing interests.

Associate Professor of Medicine

Medical Director

Lung Transplant Program

University of Chicago Hospitals

Chicago

IL

Disclosures

SMB declares that she has no competing interests.

Use of this content is subject to our disclaimer